Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
暂无分享,去创建一个
K. Flaherty | J. Wargo | D. Fisher | Alexandria P. Cogdill | C. Ferrone | D. Lawrence | H. Tsao | Andrea Boni | Cristina R. Ferrone | Durga Udayakumar | C. Sloss | P. Dang | C. Njauw
[1] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[2] K. Flaherty,et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] W. Sellers,et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.
[5] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[6] D. Hwang,et al. Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[8] S. Rosenberg,et al. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. , 2009, Journal of immunological methods.
[9] D. Schadendorf,et al. Melanoma and immunotherapy. , 2009, Hematology/oncology clinics of North America.
[10] F. Marincola,et al. Antitumor vaccines, immunotherapy and the immunological constant of rejection. , 2009, IDrugs : the investigational drugs journal.
[11] K. Flaherty,et al. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. , 2009, Cancer research.
[12] K. Flaherty,et al. Integrating BRAF/MEK inhibitors into combination therapy for melanoma , 2009, British Journal of Cancer.
[13] M. McMahon,et al. Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival , 2008, Pigment cell & melanoma research.
[14] Jeffrey Weber,et al. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). , 2008, The oncologist.
[15] Helen Pickersgill,et al. Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF , 2008, PloS one.
[16] R. Dummer,et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. , 2008 .
[17] S. Rosenberg,et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.
[18] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[19] H. Tsao,et al. Genetics of melanoma tumorigenesis , 2007, The British journal of dermatology.
[20] I. S. Dunn,et al. Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression , 2006, Molecular Cancer Research.
[21] S. Rosenberg,et al. Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression , 2004, Journal of immunotherapy.
[22] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[23] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.